Mitsui Chemicals Bets ¥1.84 Trillion on JSR, Almost Three Times Its Market Value
The 9 November agreement hands JSR, which Mitsui ranks second worldwide in advanced photoresists, to a buyer worth ¥664.6 billion. A ¥1.64 trillion bridge loan, a state bank and up to ¥150 billion of new shares pay for it.

Mitsui Chemicals agreed on 9 November to buy JSR, the Tokyo-based maker of photoresists for chipmaking, from funds run by JIC Capital, the investment arm of the state-backed Japan Investment Corporation. The price is ¥1.84 trillion, about $11.6 billion at the rate of 158.45 yen to the dollar Reuters used, made up of ¥1,392.1 billion of equity value and ¥447.9 billion of interest-bearing debt and other items.
It is a signed share purchase agreement, approved by Mitsui’s board, not a completed deal. Completion needs competition and foreign investment clearances in Japan and abroad, and Mitsui is aiming for the second half of the fiscal year to March 2028. The final price will be adjusted at closing.
The buyer is smaller than what it is buying. Mitsui’s market value was ¥664.6 billion at the close on 6 November, Reuters reported, citing LSEG data, so the price is almost three times the company’s own worth on the stock market. Its shares fell 8.5% on 9 November.
How the ¥1.84 Trillion Is Paid For
Mitsui is not paying alone. The government-owned Development Bank of Japan, DBJ, is co-investing ¥200 billion, and after completion its JSR shares will be converted into non-voting preferred shares, leaving Mitsui with all the voting rights. The rest comes from a ¥1.64 trillion bridge loan from Mitsui’s main banks, which also covers JSR’s working capital after the deal and transaction costs, according to the company’s notice to the Tokyo Stock Exchange.
That loan is about 1.7 times the ¥958.8 billion of interest-bearing debt Mitsui carried at the end of September. The company expects net debt to exceed four times EBITDA for a time after completion, and has set out how it will refinance. It will cap new common shares, including treasury shares, at ¥150 billion, and consider ¥300 billion of mezzanine financing, half of which it assumes rating agencies will count as equity. The rest would be bank loans and bonds, with the aim of keeping an issuer rating in the A category.
A shelf registration for up to ¥150 billion of new shares takes effect on 17 November and runs to 16 November 2028, with SMBC Nikko Securities and Mizuho Securities expected as lead underwriters. The proceeds would repay part of the bridge loan.
Mitsui’s investor presentation puts the headline multiple at 16 times JSR’s expected EBITDA of about ¥110 billion for the current year. It falls to 12 times if Mitsui delivers the ¥40 billion of extra annual profit it targets by fiscal 2035, half from cost savings and half from sales.
What JSR Makes for Chipmakers and What It Earns
Photoresists are the light-sensitive coatings used to transfer circuit patterns on to silicon wafers. Mitsui’s presentation describes JSR as number two in the global market for ArF and EUV photoresists, the grades used in leading-edge lithography, and as the only company able to offer both chemically amplified and metal oxide resists for EUV. Those are Mitsui’s claims, not independent market data.
The numbers explain the appetite. JSR’s semiconductor materials sales rose to ¥196.0 billion in the year to March 2026 from ¥157.9 billion. Its digital solutions division, which also includes display and optical materials, earned ¥63.2 billion before special items on sales of ¥252.1 billion, a 25.1% margin. Mitsui’s own ICT business earned ¥36.9 billion in fiscal 2025. Overseas customers took 71% of JSR’s sales.
Not every part of JSR pays its way. Inpria, its US unit developing metal oxide resists for EUV, had sales of $60.1 million in 2025 and an operating loss of $42.3 million. JSR says it will keep treating its life sciences business, which offers contract research and drug manufacturing, as non-core and explore all options, and Mitsui’s presentation lists its divestiture among the steps to cut debt.
Chip supply chains are being rebuilt around artificial intelligence demand across the industry, as Marvell’s agreed purchase of Lumentum showed in optical networking. Mitsui’s pitch is that JSR makes it one of Japan’s leading semiconductor materials companies by sales.
Japan’s State Investors Pass JSR On
The seller is a state fund. JIC Capital took JSR private through a tender offer completed on 16 April 2024, and JSR was delisted from the Tokyo Stock Exchange on 25 June 2024. Reuters put the cost at about ¥900 billion and reported that JIC’s stated aim at the time was to consolidate the chip materials sector.
Shogo Ikeuchi, JIC Capital’s chief executive, told Reuters that seven or eight potential buyers had been considered since the spring, and that the deciding question was whether a buyer could become a semiconductor materials platform for Japan over the next decade. Reuters first reported in May that JIC was weighing a sale.
The result keeps JSR in Japanese hands, with a state lender in the capital structure but without a vote. DBJ already holds JSR’s Class B preferred shares and Mizuho Bank its Class A preferred shares, which Mitsui will also buy on terms still to be agreed. The release does not show how much of the price goes to JIC’s funds rather than to those holders, so JIC’s return cannot be calculated from it.
The policy backdrop is the contest over chip technology. Washington restricts exports of advanced chips and chipmaking technology to China, and supply-chain resilience was on the agenda when Donald Trump and Xi Jinping met at the White House in September. Japan’s state fund has now chosen a domestic owner for a company Mitsui ranks second in the world in advanced resists.
The Balance Sheet Behind the 8.5% Fall
Investors had some warning. On 4 November, after media reports that it would buy JSR, Mitsui said it was considering various possibilities but had made no decision. Reuters reported that the shares had been sliding since its report of the talks the previous week, and they fell a further 8.5% on the day of the announcement. Business News Today put the close at ¥1,586, down ¥147.
The concern is arithmetic. Mitsui’s total equity was ¥1,041.6 billion at the end of September and its net debt to equity ratio 0.84. Its targets, within three years of closing, are net debt below four times EBITDA and below 1.5 times equity, with goodwill no larger than equity. Large acquisitions are on hold until then, and the company says it will keep a total shareholder return ratio of 40% and a dividend of at least ¥75 a share.
Disposals are part of the plan, worth ¥350 billion or more in business value by Mitsui’s estimate, and the company will widen the planned separation of its basic and green materials business to include its mobility unit.
A Long Wait for Regulators in Japan and Abroad
The release does not list the jurisdictions whose approval is needed, and Mitsui says it is difficult to predict how long the reviews will take. According to its presentation, JSR has plants in Japan, the US, Europe, China, South Korea and Taiwan, and Inpria and the life sciences companies are based in the US.
Japan has let a state fund sell to a domestic buyer with a state bank alongside. Brussels, by contrast, is still debating whether scale has become a competitive advantage worth easing merger rules for.
The first date to watch is 17 November, when the shelf registration takes effect and Mitsui can issue up to ¥150 billion of shares, although it says timing will depend on the deal’s progress. The second is the regulatory clock, which Mitsui expects to run into the second half of the fiscal year to March 2028.
Tags
Key Concepts
Sources
Where the reporting above comes from. Follow these to check the figures and statements for yourself.
- Mitsui Chemicals, Notice regarding execution of a share purchase agreement for shares of JSR Corporation Price and its breakdown, DBJ’s non-voting stake, conditions and timetable, the bridge loan, refinancing plan, shelf registration and JSR’s financial results.
- Mitsui Chemicals, Explanation of the JSR acquisition to drive a major portfolio transformation Chief executive presentation with JSR’s market position as Mitsui describes it, segment results, the 16 times EBITDA multiple, synergy targets and financial targets.
- Mitsui Chemicals, Regarding recent media reports The company’s statement that no decision had been made, issued after reports of the deal.
- Mitsui Chemicals, Summary of consolidated financial results for the first half of FY2026 Interest-bearing debt, total equity and the net debt to equity ratio at 30 September 2026.
- The Star (Reuters), Mitsui Chemicals and DBJ to buy JSR for $11.6 billion, filing shows Reuters report with the share price fall, Mitsui’s market value, JIC’s 2024 purchase price and comments from JIC Capital’s chief executive.
- Nippon.com (Jiji Press), Mitsui Chemicals announces deal to acquire JSR Jiji Press report of the Tokyo press conference by the three companies.
- Business News Today, Mitsui Chemicals’ $11.6bn JSR acquisition and the debt it brings Closing share price on 9 November.

